Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEA: Switching to Mesalazine Monotherapy vs Continuing Thiopurines in Older Patients With Ulcerative Colitis
NCT07248644Phase 4Not yet recruiting
- Sponsor
- GETECCU
- Start
- May 2026
- Primary completion
- Sep 2026
01
Overview
Phase 4, randomised, open-label trial in ulcerative colitis (UC) (2 arms), sponsored by GETECCU. Primary endpoint: Biologic Relapse at 24 months. Planned start May 2026; status: not yet recruiting.
02
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07248644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07248644.